To stop the continuing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, new COVID-19 vaccinations are now available. We examined the effectiveness of the most recent COVID-19 vaccinations in preventing both symptomatic COVID-19 in the elderly population and severe and symptomatic illness in adults. Up to August 30, 2021, prominent medical databases were examined. Included were published phase 3 randomized controlled trials (RCTs) that assessed the vaccine's effectiveness in preventing symptomatic and severe COVID-19 in adults. Separate reviews by two reviewers retrieved summary data and independently assessed the literature search findings. The Cochrane Risk of Bias Assessment Tool was used to assess the risk of bias. As per PRISMA-NMA 2015, we conducted a network metaanalysis (NMA) to aggregate indirect comparisons between several vaccinations for their respective efficacy. The main results were how well the adult COVID-19 vaccination worked against symptoms (PROSPERO registration number: CRD42021235364). In NMA, almost 200,000 adult participants were drawn from eight phase 3 RCTs; of these, 52% were given the intervention (active COVID-19 vaccination). Based on indirect comparison, BNT162b2 and mRNA-1273 vaccines were found to have the highest probability of efficacy against symptomatic COVID-19 (P-scores 0.952 and 0.843, respectively), followed by Gam-COVID-Vac (P-score 0.782), NVX-CoV23730 (P-score 0.700), CoronaVac (P-score 0.570), BN02 (P-score 0.428), WIV04 (P-score 0.327), and Ad26.COV2.S (P-score 0.198). All nine vaccines were tested in a unique clinical trial and compared to the control group. There was no statistically significant difference seen in the immunizations' capacity to prevent illness symptoms in the senior population. mRNA-1273 and Gam COVID-Vac had the highest P-scores (0.899 and 0.816, respectively), suggesting stronger protection against severe illness than other vaccinations; nonetheless, neither vaccine was statistically significantly related with a lower risk for severe COVID-19 than other vaccines. The mRNA-based BNT162b2 and mRNA1273 vaccines were shown to have the best efficacy against symptomatic COVID-19 in our indirect comparison with other vaccinations. This finding may be significant when choosing which vaccination to administer, along with other crucial considerations including patient acceptance, price, logistics, side effects, and vaccine availability.

To stop the continuing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, new COVID-19 vaccinations are now available.